NMT Medical wins patent case against Cardia
The U.S. District Court for the District of Minnesota has issued a ruling that Cardia of Burnsville, Minn., has infringed NMT Medical’s U.S. Patent No. 5.451.235 (235 Patent) for septal occluders, and also confirmed the validity of the patent.
The patent infringement lawsuit was originally filed in September 2004 alleging that Cardia’s Intrasept device infringes upon the 235 Patent, which is owned by the Children’s Medical Center (CMCC) and licensed exclusively by NMT of Boston.
The ruling states that Cardia's Intrasept device infringed CMCC's patent covering septal occluders, a type of medical implant used to repair intracardiac defects.
John Ahern, NMT's president and CEO, said, “We were confident that our intellectual property had been violated in the Cardia case.”
The patent infringement lawsuit was originally filed in September 2004 alleging that Cardia’s Intrasept device infringes upon the 235 Patent, which is owned by the Children’s Medical Center (CMCC) and licensed exclusively by NMT of Boston.
The ruling states that Cardia's Intrasept device infringed CMCC's patent covering septal occluders, a type of medical implant used to repair intracardiac defects.
John Ahern, NMT's president and CEO, said, “We were confident that our intellectual property had been violated in the Cardia case.”